Amgen Reports Strong Q1 Performance and Raises Full-Year Guidance
Amgen delivered a strong first quarter, with its six key growth drivers accounting for nearly 70% of sales and growing collectively by 24%. The company raised full-year revenue guidance to $37.1–$38.5 billion and non-GAAP EPS to $21.70–$23.10 while maintaining a strong operating margin.
Tickers: $AMGN
Topics: biotech earnings guidance pharmaceuticals product_growth